Palvella Therapeutics appoints Matthew Pauls to Board of Directors

PALVELLA THERAPEUTICS, INC.

Board expanded from 7 to 8 members; Pauls appointed as Class I director effective June 29, 2026.
Pauls is CEO of Savara (NASDAQ: SVRA) and has led rare disease biopharma companies including Strongbridge.
He received an option to purchase 6,000 shares vesting monthly over 36 months under the Director Compensation Policy.
Board determined Pauls is independent under Nasdaq listing rules; no related party transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthew Pauls

Class I director

PVLA · PALVELLA THERAPEUTICS, INC.

Effective: 2026-06-29
Filed: June 30, 2026, 7:36 AM ET

appointed Matthew Pauls, to serve as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Pauls was appointed as Class I director at PALVELLA THERAPEUTICS, INC..

Action: appointed
Role: Class I director

Exact text from the filing

appointed Matthew Pauls, to serve as a Class I director

View on SEC.gov

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-079087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.